Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance

European Urology

Volumn 59, Issue 3, 2011, Pages 422-429

  Ploussard, Guillaume ^a,c   Durand, Xavier ^a,c   Xylinas, Evanguelos ^a,c   Moutereau, Stéphane ^a,c   Radulescu, Camélia ^a   Forgue, Aurélien ^b   Nicolaiew, Nathalie ^c   Terry, Stéphane ^c   Allory, Yves ^a,c   Loric, Sylvain ^a,c   Salomon, Laurent ^a,c   Vacherot, Francis ^c   De La Taille, Alexandre ^a,c  

^a HENRI MONDOR HOSPITAL   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Active surveillance; Insignificant; Low risk; Prostate cancer; Prostate cancer antigen 3; Radical prostatectomy

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RISK; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; GLEASON SCORE; HUMAN; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; URINALYSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 79551478699     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.11.044     Document Type: Article

References (30)

1. P.J. Bastian, B.H. Carter, and A. Bjartell Insignificant prostate cancer and active surveillance: from definition to clinical implications Eur Urol 55 2009 1321 1332
2. R.C.N. van den Bergh, S. Roemeling, and M.J. Roobol Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1 8
3. M.W. Kattan, J.A. Eastham, and T.M. Wheeler Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors J Urol 170 2003 1792 1797
4. N. Suardi, U. Capitanio, and F.K. Chun Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features Cancer 113 2008 2068 2072
5. S.L. Conti, M. Dall'era, V. Fradet, J.E. Cowan, J. Simko, and P.R. Carroll Pathological outcomes of candidates for active surveillance of prostate cancer J Urol 181 2009 1628 1633
6. R. Choo, L. Klotz, and C. Danjoux Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression J Urol 167 2002 1664 1669
7. M.I. Patel, D.T. DeConcini, E. Lopez-Corona, M. Ohori, T. Wheeler, and P.T. Scardino An analysis of men with clinically localized prostate cancer who deferred definitive therapy J Urol 171 2004 1520 1524
8. J.L. Mohler, B.T. Williams, and J.A. Freeman Expectant management as an option for men with stage T1c prostate cancer: a preliminary study World J Urol 15 1997 364 368
9. N. Mottet, and J. Irani Active surveillance in prostate cancer: the French protocol Prog Urol 18 2008 F12 F16
10. G. Ploussard, L. Salomon, and E. Xylinas Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance - does the risk of misclassification vary according to biopsy criteria? J Urol 183 2010 539 544
11. R. Abouassaly, B.R. Lane, and J.S. Jones Staging saturation biopsy in patients with prostate cancer on active surveillance protocol Urology 71 2008 573 577
12. R.K. Berglund, T.A. Masterson, K.C. Vora, S.E. Eggener, J.A. Eastham, and B.D. Guillonneau Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance J Urol 180 2008 1964 1967
13. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534 538
14. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804 1809
15. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975 1978
16. D. Hessels, M.P. van Gils, and O. van Hooij Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10 16
17. M.E. Chen, D. Johnston, A.O. Reyes, C.P. Soto, R.J. Babaian, and P. Troncoso A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume Am J Surg Pathol 27 2003 1291 1301
18. J.I. Epstein, D.W. Chan, and L.J. Sokoll Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings J Urol 160 1998 2407 2411
19. N.J. van As, A.R. Norman, and K. Thomas Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 54 2008 1297 1305
20. A. Shukla-Dave, H. Hricak, and M.W. Kattan The utility of magnetic resonance Imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis BJU Int 99 2007 786 793
21. M.A. Dall'Era, B.R. Konety, and J.E. Cowan Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664 2670
22. K.L. Greene, E.P. Elkin, A. Karapetian, J. Duchane, P.R. Carroll, and C.J. Kane CaPSURE Investigators. Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE J Urol 175 2006 125 129
23. A. Haese, A. de la Taille, and H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081 1088
24. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1592
25. F.K. Chun, A. de la Taille, and H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659 668
26. M.J. Roobol, F.H. Schröder, and P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
27. M. Auprich, A. Haese, and J. Walz External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome Eur Urol 58 2010 727 732
28. S. Perdon, V. Cavadas, and G. Di Lorenzo Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3 Eur Urol 59 2011 81 87
29. M. Auprich, F.K.-H. Chun, and J.F. Ward Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96 105
30. N.J. van As, N.M. de Souza, and S.F. Riches A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance Eur Urol 56 2009 981 988